Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GOSS 
Gossamer Bio Inc (GOSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: GOSS (1-star) is a SELL. SELL since 1 days. Profits (19.59%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 9.78% | Avg. Invested days 30 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 265.85M USD | Price to earnings Ratio - | 1Y Target Price 7.61 |
Price to earnings Ratio - | 1Y Target Price 7.61 | ||
Volume (30-day avg) 1714691 | Beta 1.86 | 52 Weeks Range 0.50 - 1.55 | Updated Date 03/30/2025 |
52 Weeks Range 0.50 - 1.55 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.168 | Actual -0.15 |
Profitability
Profit Margin -49.28% | Operating Margin (TTM) -385.2% |
Management Effectiveness
Return on Assets (TTM) -11.94% | Return on Equity (TTM) -122.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 174212875 | Price to Sales(TTM) 2.32 |
Enterprise Value 174212875 | Price to Sales(TTM) 2.32 | ||
Enterprise Value to Revenue 1.52 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 227220992 | Shares Floating 183672034 |
Shares Outstanding 227220992 | Shares Floating 183672034 | ||
Percent Insiders 3.28 | Percent Institutions 76.5 |
Analyst Ratings
Rating 4.22 | Target Price 7.61 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Gossamer Bio Inc
Company Overview
History and Background
Gossamer Bio, Inc. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. It was founded in 2015 and went public in 2019. It focused on clinical-stage programs but faced setbacks and restructured.
Core Business Areas
- Product Development: Focused on advancing clinical-stage programs, primarily involving immunology and inflammation. This is paused due to a recent restructuring.
Leadership and Structure
Company leadership underwent changes in 2023 due to restructuring. Details on the current exact structure require updated sources as of late 2024.
Top Products and Market Share
Key Offerings
- Seralutinib: A dry powder formulation of inhaled seralutinib for the treatment of pulmonary arterial hypertension (PAH). Competitors include Actelion Pharmaceuticals (JNJ) and United Therapeutics (UTHR). Gossamer did not manage to reach their primary end point on the Phase 3 program of Seralutinib in PAH patients.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by high risks and rewards, long development timelines, and strict regulatory oversight.
Positioning
Gossamer Bio aimed to establish itself as a player in immunology and inflammation but has been undergoing restructuring due to clinical trial setbacks. Its competitive advantage was intended to be based on novel drug candidates.
Total Addressable Market (TAM)
The TAM varies depending on the specific disease area targeted. PAH TAM is significant, estimated in billions of dollars. Gossamer's position was to capture a share with seralutinib, but future efforts are uncertain.
Upturn SWOT Analysis
Strengths
- Experienced management team (prior to restructuring)
- Strong intellectual property portfolio (prior to restructuring)
- Clinical-stage assets with potential
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Pipeline concentration
- Recent failed trial outcomes and restructuring
Opportunities
- Potential partnerships and collaborations
- Expansion into new therapeutic areas (unlikely with current status)
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent expirations
- Financial instability
Competitors and Market Share
Key Competitors
- JNJ
- UTHR
- VTRS
- MRK
Competitive Landscape
Gossamer Bio faces intense competition from larger, more established pharmaceutical companies with greater resources and deeper pipelines.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the developmental stage of the company and recent failures.
Future Projections: Future growth is uncertain due to pipeline setbacks and strategic shift.
Recent Initiatives: Recent initiatives include corporate restructuring and exploring strategic alternatives, including potentially selling assets.
Summary
Gossamer Bio is currently facing significant challenges due to clinical trial failures and financial constraints. The company is undergoing restructuring and exploring strategic alternatives. Its future is highly uncertain and dependent on potential asset sales or a successful turnaround. Its historical performance has been weak, and current prospects are limited without further restructuring efforts or successful trial data.
Similar Companies
- JNJ
- UTHR
- VTRS
- MRK
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and represents a general overview. It is not financial advice, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gossamer Bio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2019-02-08 | Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 144 | Website https://www.gossamerbio.com |
Full time employees 144 | Website https://www.gossamerbio.com | ||
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.